


# AUMMUNE

A first-of-its-kind platform that utilizes a unique efficacy-driven selection process to individually-customize oligonucleotide cancer drugs

***Deliverables:*** Communication's strategy, branding, investor deck & website









individual & specific



drug-customization


Aimmune

Therapy. Driven by effect.



Every person is unique.  
Every cancer is unique.  
**Every treatment should be unique.**

[read more](#)





we're all unique.  
**so is aumune**

[read more](#)





we're all unique.  
**so is aumune**

[read more](#)



we're all unique.  
**so is aumune**

[read more](#)



we're all unique.  
**so is aumune**

[read more](#)





we're all unique.  
**so is aumune**

[read more](#)




we're all unique.  
**so is aumune.**

[read more](#)



# the benefits.

why we're unique.




Pretreatment  
validated efficacy



Minimizing risk for  
adverse affects



Fast pairing for  
efficient therapy



# aumune.

Aumune develops a first-of-its-kind individual drug-customization platform that utilizes a unique efficacy-driven selection process to match and produce a patient-specific tri-functional aptamer drug that synergistically induces cancer cell death and activates both innate and adaptive immune responses

we're all unique.  
**so is aumune**

[read more](#)

## about aumune.

who we are. what we do.

Aumune develops a first-of-its-kind individual drug-customization platform that utilizes a unique efficacy-driven selection process to match and produce a patient-specific tri-functional aptamer drug that synergistically induces cancer cell death and activates both innate and adaptive immune responses

## the benefits.

why we're unique.



Pretreatment  
validated efficacy



Minimizing risk for  
adverse effects



Fast pairing for  
efficient therapy


# We're all unique So is Aummunē

[Read more](#)

Aummunē develops a first-of-its-kind individual drug-customization platform that utilizes a unique efficacy-driven selection process to match and produce a patient-specific tri-functional aptamer drug that safely and synergistically induces cancer cell death and activates both innate and adaptive immune responses


## Individually tailored tri-functional aptamers

Synergistic tumoricidal and immune effects



## Tailoring the variable strand to every patient

Aummunē's platform utilizes a positive and negative selection process on a patient's tumor and healthy cell samples, to achieve a tumoricidal yet safe effect



## Let's Connect

Tel Aviv Medical Center (TAMC),  
Sammy Ofer Building, Floor 10  
Weizmann St 6, Tel Aviv-Yafo, ISRAEL  
T +972.537172700 | [info@aummunē.tech](mailto:info@aummunē.tech)







*“ Collaborating with PearlCom was an important milestone for Aummune. Their team, with its strong scientific background, effortlessly grasped the intricacies of our technology. They translated this complex understanding into a compelling, accessible narrative, enriching our brand and enhancing our connection with stakeholders. PearlCom has truly amplified our voice in the individualized medicine arena.”*

**Dr. Irit Carmi-Levy, PhD** | General Manager  
Aummune | **w.** [www.aummune.com](http://www.aummune.com) **t.** [+972-52-3706847](tel:+972-52-3706847)